

Anders W Erickson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5331762/publications.pdf>

Version: 2024-02-01

10
papers

128
citations

1683354

5
h-index

1588620

8
g-index

10
all docs

10
docs citations

10
times ranked

158
citing authors

#	ARTICLE	IF	CITATIONS
1	Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 931-939.	5.1	33
2	Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease. <i>JAMA Network Open</i> , 2020, 3, e201617.	2.8	28
3	Hazardous alcohol use and alcohol-related harm in rural and remote communities: a scoping review. <i>Lancet Public Health</i> , The, 2022, 7, e177-e187.	4.7	27
4	Necrosis and Brain Invasion Predict Radio-Resistance and Tumor Recurrence in Atypical Meningioma: A Retrospective Cohort Study. <i>Neurosurgery</i> , 2021, 88, E42-E48.	0.6	18
5	The Impact of Targeted Therapy on Intracranial Metastatic Disease Incidence and Survival. <i>Frontiers in Oncology</i> , 2019, 9, 797.	1.3	9
6	HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa136.	0.4	6
7	Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease. <i>JAMA Oncology</i> , 2021, 7, 1220.	3.4	5
8	Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis. <i>Npj Breast Cancer</i> , 2021, 7, 17.	2.3	2
9	04. ASSESSMENT OF EFFICACY AND SAFETY OF OSIMERTINIB FOR PATIENTS WITH INTRACRANIAL METASTATIC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Neuro-Oncology Advances</i> , 2020, 2, ii1-ii1.	0.4	0
10	THER-01. Targeted therapy and intracranial metastatic disease: a population-based retrospective cohort study. <i>Neuro-Oncology Advances</i> , 2021, 3, iii12-iii12.	0.4	0